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The type of distribution of PD-L1 
positive immune cells and PD-L1 
expression in tumor cells correlate 
with the development of non-classical 
differentiation in urinary bladder cancer
ABSTRACT
Background: The basic diagnostic tool of urinary bladder cancer is the histopathological assessment. 
However, it is insufficient to accurately predict the progression of this disease. There is a need to look 
for new prognostic factors that will make the therapeutic process more effective. The aim of this study is 
to evaluate the effect of activation of a PD1 – PD-L1 immune checkpoint in immune effector cells (IECs) 
and tumor cells, on the development of malignancy in the form of non-classic differentiation in urinary 
bladder cancer.
Materials and methods: 110 patients with stage pT1-pT4 urothelial bladder carcinoma who underwent radical 
cystectomy/cystoprostatectomy between 2011 and 2014 were included in the study. Tumor advancement 
(pT stage), grade (G), as well as, non-classic differentiation  frequency and number were evaluated patho-
logically. In each case, the area of the tumor containing PD-L1+ IECs was analyzed. The distribution of 
PD-L1+ immune effector cells within the tumor was also assessed as dispersed or aggregated. 
Results: The frequency of non-classic differentiation was significantly lower in urothelial bladder cancer 
tumors with a dispersed pattern of distribution of PD-L1+ IECs. A correlation between the extent of PD-L1 
expression in tumor cells and the non-classic differentiation number in UBC was identified. 
Conclusions: The distribution of cells expressing the immune checkpoint biomarker PD-L1 constitutes a 
new prognostic factor and may play a key role in the selection of individualized immunotherapy. In addi-
tion, the evaluation of non-classic differentiation in the tumor may complement the assessment of PD-L1 
expression due to its capacity to characterize the current malignant potential of the tumor, whereas the 
assessment of extent and distribution of PD-L1+ in tumor-associated immune cells indicates the functional 
status of the immune system.
Key words: PD-L1; urothelial bladder cancer; tumor microenvironment; immune cell, NDN, immune effector 
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Introduction
Histopathological assessment is an important tool 
in the diagnostics of urinary bladder cancer (UBC). The 
diagnostic standard of UBC includes the evaluation 
of the histological type and advancement defined by 
the depth of invasion (pT), lymph node status (pN), 
as well as the estimation of histological malignancy 
(G). These features are commonly acknowledged as 
prognostic factors [1]. However, accurate prediction 
of the UBC progression is still not possible. In this 
context, there is an urgent need to look for factors that 
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better characterize the development of the malignant 
potential of urinary bladder cancer. Literature sourc-
es have demonstrated that cases with non-classic 
differentiation (ND) such as nested, micropapillary, 
sarcomatoid or lymphoepithelial-like differentiation have 
a poorer prognosis. The Classification of Malignant 
Tumours of the Urinary System issued by the WHO in 
2004, included as many as 12 types of ND that could 
develop in urinary bladder cancer (squamous, glandu-
lar, trophoblastic, nested, microcystic, micropapillary, 
lymphoepithelial-like, lymphoma-like, plasmacytoid, 
sarcomatoid, and giant cell differentiation, as well as 
the non-differentiated type), confirming the significant 
value of including it in routine diagnostics [2]. Since 
then, a new approach and methodology have been 
developed for assessing ND as a prognostic factor in 
UBC. It was demonstrated that a higher percentage of 
ND and the higher number of different non-classical 
types of differentiation in one tumor was associated 
with shorter survival time in patients with UBC [3, 4]. 
The development of ND in UBC is accompanied by 
various molecular phenomena, such as the expression 
of RCAS1, OCT4 or the increased frequency of regu-
latory T cells [5–7]. Recently, researchers have been 
interested in the issue of  immune checkpoints (ICP) that 
influence the efficiency of effector cells of the immune 
system [8, 9]. One of them is the PD1-PD-L1 signalling 
pathway. Its activation in the neoplastic process is as-
sociated with a significant reduction or even complete 
elimination of the anti-cancer immune system response 
[9, 10]. The aim of this study is to evaluate the effect 
of activation of PD1 – PD-L1 immune control point in 
immune effector cells (IECs) and tumor cells (TCs), on 
the development of malignancy, in the form of ND in 
urinary bladder cancer.
Materials and methods
110 patients with pT1-pT4 urothelial bladder cancer 
who underwent radical cystectomy/cystoprostatec-
tomy between 2011 and 2014 were included in the 
study. The experimental group was comprised of 
patients treated at Oncology Centre Prof. Franciszek 
Łukaszczyk Memorial Hospital in Bydgoszcz (Poland). 
The mean age of patients was 65 years (65 years in 
women and in men). The clinico-pathomorphological 
characteristics of the tumors in the study group are 
presented in Table 1.
The staging and histological classification of 
tumors were assessed according to the WHO Clas-
sification of Tumors. The study was approved by the 
Committee of Ethics of Scientific Research of Collegi-
um Medicum, Nicolaus Copernicus University, Poland 
(KB 587/2018).
Table 1. Patient clinico-pathological characteristics
Patient’s characteristics Number of patients
Sex
    Female




    1
    2a
    2b
    3a
    3b
    4a









    no available
    1
    2






    0
    1
    2





The preparation and assessment of H&E stained 
samples
Tissue sections were fixed in 10% buffered for-
malin and embedded in paraffin blocks according to 
a standard protocol. Tumor advancement (pT stage), 
histological malignancy (G), frequency of ND and the 
number of non-classic differentiation types (NDN) was 
assessed as previously described [3, 11].
The preparation and assessment of 
immunostained samples
Paraffin blocks most representative of the tumor 
were selected for immunohistochemistry staining. 4 µm 
sections were stained with rabbit anti-PD-L1 (Ventana 
clone SP142, Roche) and evaluated with OptiView 
DAB IHC Detection Kit and OptiView Amplification Kit 
using the Ventana BenchMark system according to the 
manufacturer’s protocol. To confirm the specificity of 
the signal, for each sample a negative control stained 
without anti-PD-L1 antibody was provided. For each 
staining cycle, a positive control sample of human tonsil 
was included following the manufacturer’s recommen-
dations. In each test sample, the percent of tumor area 
occupied by tumor-associated immune cells exhibiting 
PD-L1 positive staining was assessed. IECs that were 
assessed included lymphocytes, macrophages, den-
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Figure 2. A low percentage of non-classic differentiation in the tumor (A) (case with ND=10%) correlates with a dispersed 
distribution pattern of PD-L1+ IECs (B). An aggregated distribution pattern of PD-L1 IECs (D) correlates with a high percentage of 
non-classic differentiation in the tumor (C) (case with ND=85%). Arrows indicate PD-L1+ IECs, arrowheads indicate tumor cells
Figure 1. The sample images show the presence of PD-L1 expression in tumor cells (A) and its absence (B)
dritic cells and granulocytes. The pattern of distribution 
of PD-L1+ IECs within the tumor was determined as 
either dispersed (Fig. 2D) or aggregated (Fig. 2B) [12]. 
In tumor cells, the expression of PD-L1 was assessed 
as either positive (Fig. 1A) or negative (Fig. 1B).
Statistical analysis
The relationships between expression of PD-L1 on 
IECs and TCs and variables such as pT, G, the extent 
of non-classic differentiation and NDN were analyzed 
using T-test for independent samples. The statistical 
analyses were performed using STATISTICA data 
analysis software (version 8.0; StatSoft, Inc., Tulsa, 
OK, USA). A p-value < 0.05 was considered to be sig-
nificant.
Results
PD-L1 positive immune cells and non-classic 
differentiation
A correlation between the extent of non-classic 
differentiation and the distribution pattern of IECs 
expressing PD-L1 in UBC was observed (Fig. 2). ND 
frequency was significantly lower in tumors with a dis-
persed distribution pattern of PD-L1+ IECs (Fig. 3).
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PD-L1+ IECs and Non-classic Differentiation in UBC
T test for independent 
samples, p = 0.030
 Average        
Average + 2Std error    
Average + 0,95*Std dev























Figure 3. In tumors presenting high dynamics of invasion, 
in which the expression of PD-L1 includes at least 80% of 
tumor cells (n=49), the extent of non-classical differentiation 
in tumors with the advantage of the aggregated presence 
of PD-L1 + IECs was almost twice as much as in tumors 
with a predominance of dispersed PD-L1 + IECs presence
Figure 4. A low number of non-classic differentiations (A) is associated with a low frequency of tumor cells expressing 
PD-L1 (B) (case with NDN = 0 and %TCs-PD-L1+ = 1%). A higher frequency of PD-L1+ tumor cells (D) can be observed 
in tumors with a higher number of non-classic differentiation types (C) (case with NDN = 2 and %TCs-PD-L1+ = 80%)
PD-L1+ TCs and NDN in UBC
T test for independent 
samples, p = 0.030
 Average        
Average + 2Std error    
Average + 0,95*Std dev
Non-classic differentiation number 



























Figure 5. The extent of PD-L1 expression in tumor cells 
was at least six times higher in tumors with non-classical 
differentiations
PD-L1 expression in tumor cells and NDN
The expression of PD-L1 on tumor cells was cor-
related with NDN in UBC samples (Fig. 4). In tumors 
with the presence of non-classic differentiation types 
(NDN>0), the extent of PD-L1 expression in tumor 
cells was significantly higher compared to tumors with-
out non-classic differentiation type (NDN = 0) (Fig. 5).
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PD-L1 expression in neoplastic cells and tumor 
stage (pT)
There was no significant correlation between PD-
L1 frequency and tumor staging (not shown).
PD-L1 expression in neoplastic cells and tumor 
grade (G)
There was no significant correlation between PD-
L1 frequency and tumor grading (not shown).
Discussion
Evaluation of PD-L1 expression in cells within a tu-
mor area is a multifaceted source of information on 
the developmental status of a tumor. Activation of the 
PD-1 – PD-L1 signalling pathway may result in not only 
a reduction of anti-cancer immune system response [9, 
10] but also drive tumor progression and malignancy 
as evidenced by increased non-classic differentiation in 
UBC [13]. Our results suggest that the effectiveness of 
the PD1 – PD-L1 immune checkpoint might depend not 
only on the expression of the ligand protein PD-L1 on 
IECs but also the pattern of distribution of those cells 
within the tumor. A dispersion of PD-L1 positive immune 
cells does not favour the frequency of non-classic dif-
ferentiation in the tumor (Fig. 2A, B). Conversely, ND is 
significantly higher in tumors with an aggregated pattern 
of distribution of PD-L1+ IECs (Fig. 2C, D, Fig. 3). This 
pattern of expression is consistent with the proposed 
mechanism of immune checkpoints and may be of key 
importance in planning immunotherapy strategies as 
the upregulation of PD-L1 expression on tumor cells 
is often accompanied by an increased expression on 
IECs as well [14]. Suppression of IECs activity by the 
activation of immune checkpoint signalling pathways 
may promote the progression of UBC [9, 15]. According 
to our knowledge, the pattern of distribution of PD-L1+ 
cells has not been evaluated in UBC before. The second 
parameter describing non-classic differentiation we 
assessed was NDN which is independent of the extent 
of ND in the tumor [3]. In our study, we observed an 
increase in NDN within tumors with a higher frequency 
of PD-L1 positive TCs (Fig. 4, Fig. 5). An increase in the 
number of non-classic histological types of differenti-
ation underlies an increase in tumor malignancy even 
if the extent of ND as a whole constitutes only a small 
percentage of the tumor area [3, 4, 11]. Pichler et al. 
demonstrated that the assessment of PD-L1 expression 
on IECs is the most reliable prognostic marker of tumor 
response to therapy. That study also highlighted high 
heterogeneity of PD-L1 expression which may help ex-
plain divergent results [16]. Altogether, an assessment 
of activated immune checkpoint pathways, expression 
of PD-L1 as well as the distribution of PD-L1 positive 
cells within the tumor should be a part of a standard 
evaluation of tumor immunological status in urothelial 
bladder cancer. In our study, the expression of PD-
L1 and distribution of PD-L1+ cells was not correlated 
with tumor advancement (pT) and grade (G).  There is 
no consensus on that matter in literature. In a study on 
lung adenocarcinoma, a correlation between high histo-
logical differentiation and PD-L1 expression on TCs and 
IECs was found [17]. Jabbour et al. found a correlation 
between PD-L1 expression on TCs and IECs and tumor 
advancement [18]. However, other studies did not con-
firm these findings [19] in line with our own results. Nu-
merous studies confirm the efficacy of inhibitors of control 
points in cancer immunotherapy [20–26]. However, not 
all patients respond to anti-PD-L1 therapy to the same 
extent which highlights the need to search for novel bio-
markers to further stratify the treatment groups [27, 28].
Conclusions
The pattern of expression of immune checkpoint 
biomarkers such as PD-L1 in tumors is a new predic-
tive tool and a potential prognostic factor in patients 
with UBC. An assessment of dispersion or aggrega-
tion patterns of cells expressing immune checkpoint 
biomarkers may play a major role in tailoring individ-
ualized immunotherapy. Moreover, the evaluation of 
ND in the tumor may complement the assessment of 
PD-L1 expression due to its capacity to characterize 
the current malignant potential of the tumor, whereas 
the assessment of extent and distribution of PD-L1+ in 
tumor-associated immune cells indicates the functional 
status of the immune system.
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